Integrated Filing — IndAS



General information about company

Scrip Code 544578
NSE Symbol RUBICON
MSEI Symbol NOTLISTED
ISIN INE506V01022
Name of company RUBICON RESEARCH LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2026
Date of end of financial year 31-03-2027
Date of board meeting when results were approved 05-11-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 27-10-2026
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter Second quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Unaudited
Segment Reporting Single segment
Description of single segment Pharmaceutical
Start date and time of board meeting 05-11-2026   14:30:00
End date and time of board meeting 05-11-2026   15:45:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Not applicable
Whether the company has any related party? Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)? No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? Yes
Latest Date on which RPT policy is updated 16-10-2025
Indicate Company website link for updated RPT policy of the Company https://www.rubicon.co.in/pdf/Related-Party-Transactions-Policy.pdf
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? No
No. of times funds raised during the quarter
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
No default in loans occurred during the quarter ended 30-09-2026. Further, the Company has not issued any debentures.



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2026 01-04-2026
B Date of end of reporting period 30-09-2026 30-09-2026
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Standalone Standalone
1 Income
Revenue from operations 38,357.20 81,130.20
Other income 226.20 467.30
Total income 38,583.40 81,597.50
2 Expenses
(a) Cost of materials consumed 13,222.60 25,767.30
(b) Purchases of stock-in-trade 0.00 0.00
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade (1,345.30) (344.10)
(d) Employee benefit expense 5,494.50 10,646.60
(e) Finance costs 646.40 1,247.70
(f) Depreciation, depletion and amortisation expense 1,061.20 2,118.00
(f) Other Expenses
1 Other Expenses 11,347.70 22,940.00
Total other expenses 11,347.70 22,940.00
Total expenses 30,427.10 62,375.50
3 Total profit before exceptional items and tax 8,156.30 19,222.00
4 Exceptional items 0.00 0.00
5 Total profit before tax 8,156.30 19,222.00
6 Tax expense
7 Current tax 1,962.30 4,267.50
8 Deferred tax 132.00 647.60
9 Total tax expenses 2,094.30 4,915.10
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations 6,062.00 14,306.90
12 Profit (loss) from discontinued operations before tax 0.00 0.00
13 Tax expense of discontinued operations 0.00 0.00
14 Net profit (loss) from discontinued operation after tax 0.00 0.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0.00 0.00
16 Total profit (loss) for period 6,062.00 14,306.90
17 Other comprehensive income net of taxes (149.30) (144.10)
18 Total Comprehensive Income for the period 5,912.70 14,162.80
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 1,655.30 1,655.30
Face value of equity share capital 1 1
27 Details of debt securities
22 Reserves excluding revaluation reserve
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 3.66 8.65
Diluted earnings (loss) per share from continuing operations 3.63 8.56
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 3.66 8.65
Diluted earnings (loss) per share from continuing and discontinued operations 3.63 8.56
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results

Textual Information(1) See accompanying notes to the standalone financial results available at https://www.bseindia.com/xml-data/corpfiling/AttachLive/6d75b70a-fe2d-475f-8fd3-11fb2893af27.pdf Research and development revenue expenditure incurred (included above): Rs. 639.76 Millions for quarter ended 30-09-2026; Rs. 1,236.52 Millions for half year ended 30-09-2026.



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2026
Date of end of reporting period 30-09-2026
Whether results are audited or unaudited Unaudited
Nature of report standalone or consolidated Standalone
Assets
1 Non-current assets
Property, plant and equipment 40,749.80
Capital work-in-progress 3,344.70
Investment property 0.00
Goodwill 0.00
Other intangible assets 888.10
Intangible assets under development 120.10
Biological assets other than bearer plants 0.00
Investments accounted for using equity method 0.00
Non-current financial assets
Non-current investments 22,229.30
Trade receivables, non-current 0.00
Loans, non-current 349.70
Other non-current financial assets
1 Other financial assets 5,787.50
Total of other non-current financial assets 5,787.50
Total non-current financial assets 28,366.50
Deferred tax assets (net) 0.00
Other non-current assets
1 Other non-current assets 3,304.90
2 Non Current Tax assets (net) 1,421.60
Total of other non-current assets 4,726.50
Total non-current assets 78,195.70
2 Current assets
Inventories 38,979.30
Current financial asset
Current investments 0.00
Trade receivables, current 76,719.10
Cash and cash equivalents 9,858.50
Bank balance other than cash and cash equivalents 6,775.20
Loans, current 50.00
Other current financial assets
Total of other current financial assets 5,074.50
Total current financial assets 98,477.30
Current tax assets (net) 0.00
Other current assets
1 Other current assets 5,343.00
Total of other current assets 5,343.00
Total current assets 1,42,799.60
3 Non-current assets classified as held for sale 0.00
4 Regulatory deferral account debit balances and related deferred tax Assets 0.00
Total assets 2,20,995.30
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 1,655.30
Other equity 1,46,797.70
Total equity attributable to owners of parent 1,48,453.00
Non controlling interest
Total equity 1,48,453.00
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 18,847.50
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises 0.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 0.00
Total Trade payable 0.00
Other non-current financial liabilities
1 Lease liabilities 757.40
2 Other Financial Liabilities 637.40
Total of other non-current financial liabilities 1,394.80
Total non-current financial liabilities 20,242.30
Provisions, non-current 1,687.80
Deferred tax liabilities (net) 64.20
Deferred government grants, Non-current 0.00
Other non-current liabilities
Total of other non-current liabilities
Total non-current liabilities 21,994.30
Current liabilities
Current financial liabilities
Borrowings, current 20,989.50
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 89.20
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 24,196.90
Total Trade payable 24,286.10
Other current financial liabilities
1 Lease liabilities 616.30
2 Other financial liabilities 3,713.80
Total of other current financial liabilities 4,330.10
Total current financial liabilities 49,605.70
Other current liabilities 726.20
1 Other current liabilities 726.20
Total of other current liabilities 726.20
Provisions, current 193.30
Current tax liabilities (Net) 22.80
Deferred government grants, Current 0.00
Total current liabilities 50,548.00
3 Liabilities directly associated with assets in disposal group classified as held for sale 0.00
4 Regulatory deferral account credit balances and related deferred tax liability 0.00
Total liabilities 72,542.30
Total equity and liabilites 2,20,995.30
Disclosure of notes on assets and liabilities



Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-07-2026 01-04-2026
Date of end of reporting period 30-09-2026 30-09-2026
Whether results are audited or unaudited Unaudited Unaudited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2026 01-04-2026
B Date of end of reporting period 30-09-2026 30-09-2026
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Items that will not be reclassified to profit or loss (199.60) (192.60)
Total Amount of items that will not be reclassified to profit and loss (199.60) (192.60)
2 Income tax relating to items that will not be reclassified to profit or loss (50.30) (48.50)
3 Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4 Income tax relating to items that will be reclassified to profit or loss 0.00 0.00
5 Total Other comprehensive income (149.30) (144.10)



Cash flow statement, indirect

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2026
B Date of end of reporting period 30-09-2026
C Whether results are audited or unaudited Unaudited
D Nature of report standalone or consolidated Standalone
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 19,222.00
Adjustments for reconcile profit (loss)
Adjustments for finance costs 1,247.70
Adjustments for decrease (increase) in inventories (4,197.30)
Adjustments for decrease (increase) in trade receivables, current (6,391.40)
Adjustments for decrease (increase) in trade receivables, non-current 0.00
Adjustments for decrease (increase) in other current assets 1,572.30
Adjustments for decrease (increase) in other non-current assets 0.00
Adjustments for other financial assets, non-current (1,982.50)
Adjustments for other financial assets, current 0.00
Adjustments for other bank balances 0.00
Adjustments for increase (decrease) in trade payables, current (1,717.80)
Adjustments for increase (decrease) in trade payables, non-current 0.00
Adjustments for increase (decrease) in other current liabilities (1,184.90)
Adjustments for increase (decrease) in other non-current liabilities 0.00
Adjustments for depreciation and amortisation expense 2,118.00
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0.00
Adjustments for provisions, current 291.10
Adjustments for provisions, non-current 0.00
Adjustments for other financial liabilities, current 88.10
Adjustments for other financial liabilities, non-current 0.00
Adjustments for unrealised foreign exchange losses gains 1,512.70
Adjustments for dividend income 0.80
Adjustments for interest income 349.70
Adjustments for share-based payments 62.80
Adjustments for fair value losses (gains) (1,676.80)
Adjustments for undistributed profits of associates 0.00
Other adjustments for which cash effects are investing or financing cash flow 0.00
Other adjustments to reconcile profit (loss) (8.20)
Other adjustments for non-cash items 18.20
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0.00
Total adjustments for reconcile profit (loss) (10,598.50)
Net cash flows from (used in) operations 8,623.50
Dividends received 0.00
Interest paid 0.00
Interest received 0.00
Income taxes paid (refund) 4,265.80
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) operating activities 4,357.70
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0.00
Cash flows used in obtaining control of subsidiaries or other businesses 17,591.70
Other cash receipts from sales of equity or debt instruments of other entities 0.00
Other cash payments to acquire equity or debt instruments of other entities 0.00
Other cash receipts from sales of interests in joint ventures 0.00
Other cash payments to acquire interests in joint ventures 0.00
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0.00
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0.00
Proceeds from sales of property, plant and equipment 14.10
Purchase of property, plant and equipment 4,912.10
Proceeds from sales of investment property 0.00
Purchase of investment property 0.00
Proceeds from sales of intangible assets 0.00
Purchase of intangible assets 0.00
Proceeds from sales of intangible assets under development 0.00
Purchase of intangible assets under development 0.00
Proceeds from sales of goodwill 0.00
Purchase of goodwill 0.00
Proceeds from biological assets other than bearer plants 0.00
Purchase of biological assets other than bearer plants 0.00
Proceeds from government grants 0.00
Proceeds from sales of other long-term assets 0.00
Purchase of other long-term assets 0.00
Cash advances and loans made to other parties 0.00
Cash receipts from repayment of advances and loans made to other parties 0.00
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0.00
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0.00
Dividends received 0.80
Interest received 385.10
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 8,775.40
Net cash flows from (used in) investing activities (13,328.40)
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0.00
Payments from changes in ownership interests in subsidiaries 0.00
Proceeds from issuing shares 432.50
Proceeds from issuing other equity instruments 0.00
Payments to acquire or redeem entity's shares 0.00
Payments of other equity instruments 0.00
Proceeds from exercise of stock options 0.00
Proceeds from issuing debentures notes bonds etc 0.00
Proceeds from borrowings 16,203.60
Repayments of borrowings 3,099.10
Payments of lease liabilities 292.70
Dividends paid 2,482.20
Interest paid 1,171.10
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 16.10
Net cash flows from (used in) financing activities 9,607.10
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes 636.40
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 44.20
Net increase (decrease) in cash and cash equivalents 680.60
Cash and cash equivalents cash flow statement at beginning of period 9,177.90
Cash and cash equivalents cash flow statement at end of period 9,858.50





Amount in (Lakhs)

Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)

Sr No. Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
Details of the party (listed entity/subsidiary) entering into the transaction Details of the counterparty Type of related party transaction Details of other related party transaction Value of the related party transaction as approved by the audit committee Remarks on approval by audit committee Value of the related party transaction ratified by the audit committee Date of Audit Committee Meeting where the ratification was approved Value of transaction during the reporting period In case monies are due to either party as a result of the transaction In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments Details of the loans, inter-corporate deposits, advances or investments Notes
Name PAN Name PAN Relationship of the counterparty with the listed entity or its subsidiary Opening balance Closing balance Nature of indebtedness (loan/ issuance of debt/ any other etc.) Details of other indebtedness Cost Tenure Nature (loan/ advance/ intercorporate deposit/ investment ) Interest Rate (%) Tenure Secured/ unsecured Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
1 Rubicon Research Limited Pratibha Pilgaonkar Managing Director Remuneration 200.00 Approved 97.60 0.00 0.00
2 Rubicon Research Limited Parag Sancheti Executive Director and Chief Executive Officer Remuneration 800.00 Approved 446.70 0.00 0.00
3 Rubicon Research Limited Sumant Pilgaonkar SMP and Promoter Remuneration 200.00 Approved 120.30 0.00 0.00
4 Rubicon Research Limited Sudhir Pilgaonkar SMP and Promoter Remuneration 41.00 Approved 19.80 0.00 0.00
5 Rubicon Research Limited Surabhi Sancheti SMP and Promoter Remuneration 315.00 Approved 186.20 0.00 0.00
6 Rubicon Research Limited Otrio Ventures Pvt Ltd. Entity in which KMP or relatives of KMP have control or significant influence Purchase of goods or services 30.00 Approved 13.90 0.00 0.00
7 Rubicon Research Limited MedOne Pharma Labs Entity in which KMP or relatives of KMP have control or significant influence Any other transaction Leave and License Fees 650.00 Approved 310.20 0.00 0.00
8 Rubicon Research Limited AdvaGen Pharma Limited Subsidiary Sale of goods or services 1,50,000.00 Approved 65,996.00 0.00 0.00
9 Rubicon Research Limited Rubicon Consumer Healthcare Private Limited Subsidiary Sale of goods or services 150.00 Approved 4.00 0.00 0.00
10 AdvaGen Pharma Europe OU AdvaGen Pharma Limited Fellow Subsidiary Sale of goods or services 30,000.00 Approved 8,805.60 0.00 0.00
11 Rubicon Research Limited Validus Pharmaceuticals LLC Subsidiary Sale of goods or services 15,000.00 Approved 361.30 0.00 0.00
12 AdvaGen Pharma Europe OU Rubicon Research Limited Holding Company Sale of goods or services 10,000.00 Approved 307.00 0.00 0.00
13 Rubicon Research Limited Rubicon Consumer Healthcare Private Limited Subsidiary Interest received 15.00 Approved 7.50 0.00 0.00
14 Rubicon Research Limited Rubicon Research Private Limited (Singapore) Subsidiary Interest received 6.00 Approved 2.10 0.00 0.00
15 Rubicon Research Limited Kia Health Tech Private Limited Subsidiary Interest received 4.00 Approved 1.90 0.00 0.00
16 Rubicon Research Limited Rubicon Research Australia Pty Ltd Subsidiary Interest received 5.00 Approved 2.60 0.00 0.00
17 AdvaGen Pharma Limited AdvaGen Holding Inc Holding Company Interest received 250.00 Approved 262.00 0.00 0.00
18 AdvaGen Pharma Limited Validus Pharmaceuticals LLC Fellow Subsidiary Interest received 0.00 Approved 9.90 0.00 0.00
19 Rubicon Research Limited Rubicon Research Canada Limited Subsidiary Any other transaction Product development expenses 6,000.00 Approved 2,579.80 0.00 0.00
20 Rubicon Research Limited AdvaGen Pharma Limited Subsidiary Any other transaction Royalty income 1,500.00 Approved 625.60 0.00 0.00
21 Rubicon Research Limited AdvaGen Pharma Limited Subsidiary Any other transaction Commission On Corporate Guarantee 400.00 Approved 71.40 0.00 0.00
22 AdvaGen Pharma Limited AIM RX3PL L.L.C Fellow Subsidiary Any other transaction Warehousing/Freight expenses 10,450.00 Approved 1,960.80 0.00 0.00
23 Validus Pharmaceuticals LLC AIM RX3PL L.L.C Fellow Subsidiary Any other transaction Warehousing/Freight expenses 1,425.00 Approved 111.00 0.00 0.00
24 Rubicon Research Limited Rubicon Consumer Healthcare Private Limited Subsidiary Any other transaction Management service income 6.00 Approved 3.00 0.00 0.00
25 AdvaGen Pharma Limited Validus Pharmaceuticals LLC Fellow Subsidiary Loan 0.00 Not Applicable 1,919.40 0.00 0.00 Loan 0 1 Year Unsecured Business Purpose Textual Information(1)
26 AdvaGen Pharma Limited AdvaGen Holding Inc Holding Loan 0.00 Not Applicable 0.00 8,110.90 10,314.40
27 Rubicon Research Limited Kia Health Tech Private Limited Subsidiary Loan 0.00 Not Applicable 0.00 50.00 50.00
28 Rubicon Research Limited Rubicon Research Private Limited (Singapore) Subsidiary Loan 0.00 Not Applicable 0.00 80.40 82.60
29 Rubicon Research Limited Rubicon Research Australia Pty Ltd Subsidiary Loan 0.00 Not Applicable 0.00 64.70 67.10
30 Rubicon Research Limited Rubicon Consumer Healthcare Private Limited Subsidiary Loan 0.00 Not Applicable 0.00 200.00 200.00
31 AdvaGen Pharma Limited Validus Pharmaceuticals LLC Fellow Subsidiary Loan 0.00 Not Applicable 0.00 0.00 1,919.40
32 Rubicon Research Limited Validus Pharmaceuticals LLC Subsidiary Any other transaction Trade and Others payables 0.00 Not Applicable 0.00 206.50 210.20
33 Rubicon Research Limited AIM RX3PL L.L.C Subsidiary Any other transaction Trade and Other receivables 0.00 Not Applicable 0.00 4.70 4.80
34 Rubicon Research Limited Validus Pharmaceuticals LLC Subsidiary Any other transaction Trade and Other receivables 0.00 Not Applicable 0.00 865.70 1,245.40
35 Rubicon Research Limited Rubicon Research Canada Limited Subsidiary Any other transaction Trade and Others payables 0.00 Not Applicable 0.00 990.30 739.50
36 AdvaGen Pharma Limited Kinaxon Bio Inc Fellow Subsidiary Any other transaction Trade and Other receivables 0.00 Not Applicable 0.00 7.20 7.30
37 AdvaGen Pharma Limited AdvaGen Pharma Europe OU Fellow Subsidiary Any other transaction Advance given 0.00 Not Applicable 0.00 7,328.90 5,513.00
38 Rubicon Research Limited Rubicon Research Australia Pty Ltd Subsidiary Any other transaction Trade and Other receivables 0.00 Not Applicable 0.00 66.50 71.60
39 Rubicon Research Limited Rubicon Research Private Limited (Singapore) Subsidiary Any other transaction Trade and Other receivables 0.00 Not Applicable 0.00 37.30 49.60
40 AdvaGen Pharma Limited AdvaGen Holding Inc Holding Any other transaction Trade and Other receivables 0.00 Not Applicable 0.00 199.70 280.80
41 AdvaGen Pharma Limited AIM RX3PL L.L.C Fellow Subsidiary Any other transaction Trade and Other receivables 0.00 Not Applicable 0.00 1,044.40 1,074.70
42 AdvaGen Pharma Limited Validus Pharmaceuticals LLC Fellow Subsidiary Any other transaction Trade and Other receivables 0.00 Not Applicable 0.00 230.50 0.00
43 AdvaGen Pharma Limited Validus Pharmaceuticals LLC Fellow Subsidiary Any other transaction Trade and Others payables 0.00 Not Applicable 0.00 0.00 306.40
44 AdvaGen Holding Inc AdvaGen Pharma Limited Subsidiary Any other transaction Trade and Other receivables 0.00 Not Applicable 0.00 1,160.40 0.00
45 AdvaGen Holding Inc Validus Pharmaceuticals LLC Subsidiary Any other transaction Trade and Other receivables 0.00 Not Applicable 0.00 162.50 273.40
46 AdvaGen Holding Inc AIM RX3PL L.L.C Subsidiary Any other transaction Trade and Other receivables 0.00 Not Applicable 0.00 137.60 115.80
47 Rubicon Research Limited Rubicon Consumer Healthcare Private Limited Subsidiary Any other transaction Trade and Other receivables 0.00 Not Applicable 0.00 299.60 181.40
48 Rubicon Research Limited AdvaGen Pharma Limited Subsidiary Any other transaction Trade and Other receivables 0.00 Not Applicable 0.00 61,442.00 63,983.50
49 Rubicon Research Limited AdvaGen Pharma Europe OU Subsidiary Any other transaction Trade and Others payables 0.00 Not Applicable 0.00 0.00 304.70
50 Rubicon Research Limited AdvaGen Holding Inc Subsidiary Any other transaction Trade and Others payables 0.00 Not Applicable 0.00 139.20 238.40
51 Rubicon Research Limited Kia Health Tech Private Limited Subsidiary Any other transaction Trade and Other receivables 0.00 Not Applicable 0.00 1,520.30 2,904.60
52 AdvaGen Pharma Limited Rubicon Research Canada Limited Fellow Subsidiary Any other transaction Trade and Other receivables 0.00 Not Applicable 0.00 477.90 4.50
53 Validus Pharmaceuticals LLC AIM RX3PL L.L.C Fellow Subsidiary Any other transaction Trade and Others payables 0.00 Not Applicable 0.00 100.20 221.50
54 Rubicon Research Limited MedOne Pharma Labs Entity in which KMP or relatives of KMP have control or significant influence Any other transaction Deposits given 0.00 Not Applicable 0.00 139.40 139.40
55 Rubicon Research Limited AdvaGen Pharma Limited Subsidiary Any other transaction Guarantee given 0.00 Not Applicable 0.00 18,684.80 20,532.90
56 Rubicon Research Limited AdvaGen Pharma Limited Subsidiary Any other transaction Recovery of ESOP costs 0.00 Not Applicable 140.00 0.00 0.00
57 Rubicon Research Limited AdvaGen Holding Inc Subsidiary Any other transaction Reimbursement of expenses 0.00 Not Applicable 95.70 0.00 0.00
58 Validus Pharmaceuticals LLC AdvaGen Holding Inc Subsidiary Any other transaction Reimbursement of expenses 0.00 Not Applicable 36.40 0.00 0.00
59 AIM RX3PL L.L.C AdvaGen Holding Inc Subsidiary Any other transaction Reimbursement of expenses 0.00 Not Applicable 18.20 0.00 0.00
60 Rubicon Research Limited Rubicon Research Australia Pty Ltd Subsidiary Any other transaction Reimbursement of expenses 0.00 Not Applicable 6.00 0.00 0.00
61 Rubicon Research Limited Rubicon Research Private Limited (Singapore) Subsidiary Any other transaction Reimbursement of expenses 0.00 Not Applicable 9.10 0.00 0.00
Total value of transaction during the reporting period 84,531.00



Text Block

Textual Information(1) Interest rate shall be read as SOFR+2%